What removes bismuth from the body?
Round, biconvex, film-coated tablets, white or almost white, odorless or with a slight characteristic odor. On a cross section, two layers are visible: the core is white or white with a yellowish tint and the film shell.
pharmachologic effect
pharmachologic effect – gastroprotective, antiulcer, bactericidal, anti-inflammatory, astringent.
Pharmacodynamics
Gastroprotective and antiulcer agent with bactericidal activity against Helicobacter pylori. It also has anti-inflammatory and astringent effects. In the acidic environment of the stomach, insoluble bismuth oxychloride and citrate are precipitated, and chelate compounds are formed with the protein substrate in the form of a protective film on the surface of ulcers and erosions. Thus, the drug forms a protective layer, which for a long period of time protects the affected areas of the mucous membrane from the influence of aggressive factors. By increasing the synthesis of PGE, mucus formation and bicarbonate secretion, it stimulates the activity of cytoprotective mechanisms, increases the resistance of the gastrointestinal mucosa to the effects of pepsin, hydrochloric acid, enzymes and bile salts. Leads to the accumulation of epidermal growth factor in the defect area. Reduces the activity of pepsin and pepsinogen.
Pharmacokinetics
Practically not absorbed from the gastrointestinal tract. It is excreted mainly in feces. A small amount of bismuth entering the plasma is excreted from the body by the kidneys.
Показания
- functional dyspepsia not associated with organic gastrointestinal diseases;
- chronic gastritis and gastroduodenitis in the acute phase, including those associated with Helicobacter pylori;
- peptic ulcer of the stomach and duodenum in the acute phase, including those associated with Helicobacter pylori;
- irritable bowel syndrome, which occurs predominantly with symptoms of diarrhea.
Противопоказания
- hypersensitivity to bismuth tripotassium dicitrate or to any excipient included in the drug;
- chronic renal failure;
- pregnancy;
- the period of breastfeeding;
- age to 4 years.
Application in pregnancy and lactation
Bismuth tripotassium dicitrate is contraindicated for use in pregnant women. If it is necessary to use the drug during lactation, breastfeeding should be stopped.
Dosing and Administration
Information for healthcare professionals only.
Are you a healthcare professional?
Inside, Swallow whole, without chewing or crushing, drinking plenty of water. It is not recommended to take the tablets with milk. The duration of the course of treatment and the dose of the drug are determined by the attending physician individually for each patient, depending on the nature of the disease.
Adults and children over 12 years old the drug is prescribed 1 tablet. 4 times a day, 30 minutes before meals (breakfast, lunch, dinner) and at night, or 2 tablets. 2 times a day, 30 minutes before meals (breakfast, dinner).
Children from 8 to 12 years old – 1 table. 2 times a day, 30 minutes before meals (breakfast, dinner), from 4 to 8 years – at a dose of 8 mg/kg/day; Depending on the child’s body weight, 1–2 tablets per day are prescribed (respectively, in 1–2 doses per day). In this case, the daily dose should be as close as possible to the calculated dose (8 mg/kg/day). The tablets are taken 30 minutes before meals with a small amount of water.
The duration of treatment is usually from 4 to 8 weeks. After finishing taking the drug, it is not recommended to take medications containing bismuth (for example, Vikalin, Vikair) for 2 months.
For eradication Helicobacter pylori It is advisable to use bismuth tripotassium dicitrate in combination with antibacterial drugs with anti-Helicobacter activity.
If there is no improvement during treatment, you should consult a doctor. The drug must be used only according to the method of application and in the doses indicated in the instructions. If necessary, consult a doctor before using the drug.
Side effects
The following adverse events noted with the use of bismuth tripotassium dicitrate are distributed according to the frequency of occurrence in accordance with the following gradation: very often (≥1/10); often (≥1/100,
Gastrointestinal disorders: very often – black stool; Uncommon: nausea, vomiting, diarrhea or constipation.
This side of the immune system: uncommon – skin rash, itching; very rarely – anaphylactic reactions.
From the nervous system: very rarely – with long-term use in high doses – encephalopathy associated with the accumulation of bismuth in the central nervous system.
Side effects are reversible and disappear quickly after discontinuation of the drug.
If any of the side effects indicated in the description worsen, or the patient notices any other side effects not listed in the description, the doctor should be informed.
Antiulcer agent with bactericidal activity against Helicobacter pylori. It also has anti-inflammatory and astringent effects. In the acidic environment of the stomach, insoluble bismuth oxychloride and citrate are formed, and chelate compounds are formed with the protein substrate in the form of a protective film on the surface of ulcers and erosions. By increasing the synthesis of prostaglandin E, mucus formation and bicarbonate secretion, it stimulates the activity of cytoprotective mechanisms, increases the resistance of the gastrointestinal mucosa to the effects of pepsin, hydrochloric (hydrochloric) acid, enzymes and bile salts. Leads to the accumulation of epidermal growth factor in the defect area. Reduces the activity of pepsin and pepsinogen.
Pharmacokinetics
Bismuth tripotassium dicitrate is practically not absorbed from the gastrointestinal tract. However, small amounts of bismuth may enter the systemic circulation. It is excreted mainly in feces. A small amount of bismuth entering the plasma is excreted by the kidneys.
Indications of the active substance BISMUTH TRIPOTASSIUM DICITRATE
Peptic ulcer of the stomach and duodenum in the acute phase (including those associated with Helicobacter pylori); chronic gastritis and gastroduodenitis in the acute phase (including those associated with Helicobacter pylori); irritable bowel syndrome, which occurs predominantly with symptoms of diarrhea; functional dyspepsia not associated with organic gastrointestinal diseases.
| Code IKB-10 | Indication |
| K25 | Stomach ulcer |
| K26 | Duodenal ulcer |
| K27 | Peptic ulcer |
| K29 | Gastritis and duodenitis |
| K30 | Functional dyspepsia (digestive disorders) |
| K58 | Irritable bowel syndrome |
Dosing regimen
Adults and children over 4 years old – orally 2-4 times a day 30 minutes before meals. The dose depends on the patient’s age.
The course of treatment is 4-8 weeks. You should not take medications containing bismuth for the next 8 weeks.
To eradicate Helicobacter pylori, it is advisable to use bismuth tripotassium dicitrate in combination with antibacterial drugs that have anti-Helicobacter activity.
Side effect
From the digestive system: transient effects are possible – nausea, vomiting, increased bowel movements, constipation.
Dermatological reactions: skin rash, itching.
From the side of the central nervous system: with long-term use in high doses – encephalopathy associated with the accumulation of bismuth in the central nervous system.
Contraindications for use
Severe renal dysfunction, pregnancy, lactation, hypersensitivity to bismuth tripotassium dicitrate.
Application in pregnancy and lactation
Contraindicated for use during pregnancy and lactation (breastfeeding).
Use for renal impairment
Contraindicated in cases of severe renal impairment.
Use in children
It is used in children over 4 years of age according to the dosage regimen.
special instructions
Should not be used for more than 8 weeks.
During treatment, it is not recommended to exceed the established daily doses for adults and children.
At the end of the course of treatment in recommended doses, the concentration of the active substance in the blood plasma does not exceed 3-58 μg/l, and intoxication is observed only at a concentration of more than 100 μg/l.
During use, stool may turn black due to the formation of bismuth sulfide. Sometimes there is a slight darkening of the tongue.
Drug Interactions
If you take other medicines at the same time, as well as food and liquids, in particular antacids, milk, fruit and fruit juices, the effectiveness of bismuth tripotassium dicitrate may change.
Checked by an expert doctor Ekaterina Aleksandrovna Tolmacheva, Candidate of Medical Sciences, 43 years of experience
